282 related articles for article (PubMed ID: 8635006)
1. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.
Berek JS; Bast RC
Cancer; 1995 Nov; 76(10 Suppl):2092-6. PubMed ID: 8635006
[TBL] [Abstract][Full Text] [Related]
2. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
[TBL] [Abstract][Full Text] [Related]
3. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
4. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
5. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
Skates SJ; Horick N; Yu Y; Xu FJ; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Woolas RP; Jacobs IJ; Zhang Z; Bast RC
J Clin Oncol; 2004 Oct; 22(20):4059-66. PubMed ID: 15381683
[TBL] [Abstract][Full Text] [Related]
6. Status of tumor markers in ovarian cancer screening.
Bast RC
J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
[TBL] [Abstract][Full Text] [Related]
7. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer.
Lv XL; Zhu Y; Liu JW; Ai H
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5113-5116. PubMed ID: 28051260
[TBL] [Abstract][Full Text] [Related]
8. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
9. Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer.
Sugiyama T; Nishida T; Komai K; Nishimura H; Yakushiji M; Nishimura H
Int J Gynaecol Obstet; 1996 Sep; 54(3):251-6. PubMed ID: 8889633
[TBL] [Abstract][Full Text] [Related]
10. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.
Gorelik E; Landsittel DP; Marrangoni AM; Modugno F; Velikokhatnaya L; Winans MT; Bigbee WL; Herberman RB; Lokshin AE
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):981-7. PubMed ID: 15824174
[TBL] [Abstract][Full Text] [Related]
11. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.
Skates SJ; Xu FJ; Yu YH; Sjövall K; Einhorn N; Chang Y; Bast RC; Knapp RC
Cancer; 1995 Nov; 76(10 Suppl):2004-10. PubMed ID: 8634992
[TBL] [Abstract][Full Text] [Related]
12. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
[TBL] [Abstract][Full Text] [Related]
13. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
Onsrud M; Shabana A; Austgulen R
Tumour Biol; 1996; 17(2):90-6. PubMed ID: 8658018
[TBL] [Abstract][Full Text] [Related]
14. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
15. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma.
Shabana A; Onsrud M
Tumour Biol; 1994; 15(6):361-7. PubMed ID: 7997808
[TBL] [Abstract][Full Text] [Related]
16. Update on ovarian cancer screening.
Munkarah A; Chatterjee M; Tainsky MA
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):22-6. PubMed ID: 17218847
[TBL] [Abstract][Full Text] [Related]
17. Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
Bast RC; Knauf S; Epenetos A; Dhokia B; Daly L; Tanner M; Soper J; Creasman W; Gall S; Knapp RC
Cancer; 1991 Oct; 68(8):1758-63. PubMed ID: 1913520
[TBL] [Abstract][Full Text] [Related]
18. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
19. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
[TBL] [Abstract][Full Text] [Related]
20. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
Xi QP; Pu DH; Lu WN
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
